Long-term albumin administration in patients with cirrhosis and uncomplicated ascites: the use of serum albumin concentration for personalizing treatment

Zaccherini, Giacomo; Riggio, Oliviero; Angeli, Paolo; Alessandria, Carlo; Neri, Sergio; Foschi, F.G.; Levantesi, Fabio; Airoldi, Aldo; Simone, L.; Svegliati‐Baroni, Gianluca; Fagiuoli, S.; Romanelli, Roberto Giulio; Cozzolongo, R.; Marco, V. Di; Sangiovanni, Vincenzo; Morisco, F.; Toniutto, Pierluigi; Tortora, Annalisa; Marco, Rosanna De; Nardelli, Silvia; Piano, Salvatore; Elia, Chiara; Roncadori, Andrea; Baldassarre, Maurizio; Tufoni, Manuel; Caraceni, Paolo; Bernardi, Mauro

doi:10.1016/j.dld.2018.11.052

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After removing duplicates, 1350 articles were reviewed by title and abstract screening according to the eligibility criteria. Twenty‐five studies were selected for full‐text review, 20 of which were excluded for not meeting some of the inclusion criteria or for meeting the exclusion criterion 15–34 . Finally, five studies were included in this systematic review 7–11 .…”

Section: Resultsmentioning

confidence: 99%

Long‐term albumin administration in patients with cirrhosis and ascites: A meta‐analysis of randomized controlled trials

Sandi¹,

Leão²,

Mattos

et al. 2020

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim Ascites is a common complication of cirrhosis, and it is associated with increased mortality. The aim of this study was to evaluate the efficacy of long‐term albumin administration in decreasing mortality and other complications of patients with cirrhosis and ascites. Methods A systematic review was performed using MEDLINE and Embase databases. Randomized controlled trials evaluating long‐term albumin administration in patients with cirrhosis and ascites were considered eligible, as long as at least one of the following outcomes was evaluated: mortality, recurrence of ascites/need for paracentesis, refractory ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, gastrointestinal bleeding, or adverse events. Meta‐analysis was performed using the random‐effects model, through the Mantel–Haenszel method. The study protocol was registered at PROSPERO platform (CRD42019130078). Results The literature search yielded 1517 references. Five randomized controlled trials fulfilled the selection criteria and were included in this meta‐analysis, involving 716 individuals. Patients receiving long‐term albumin had significantly lower risk of recurrence of ascites/need for paracentesis when compared with controls (risk ratio = 0.56, 95% confidence interval = 0.48–0.67, P < 0.00001). There was no evidence of significant difference between the long‐term albumin and control groups regarding mortality, refractory ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, gastrointestinal bleeding, or adverse events. Conclusions Long‐term albumin administration in patients with cirrhosis and ascites decreases recurrence of ascites/need for paracentesis. At this point, there is no evidence of significant benefits of long‐term albumin administration regarding mortality or other complications of cirrhosis.

show abstract

Section: Resultsmentioning

confidence: 99%

Long‐term albumin administration in patients with cirrhosis and ascites: A meta‐analysis of randomized controlled trials

Sandi¹,

Leão²,

Mattos

et al. 2020

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…The beneficial effects of the administration of HSA by intravenous infusion have been highlighted in several clinical settings, such as hypovolemia, hypoalbuminemia, burns, hemorrhage and hemodialysis, as well as liver diseases characterized by an altered albumin metabolism [10]. The production of pharmaceutical-grade HSA is based on the isolation and purification of the protein from the plasma of donors, a process that includes a pasteurization step to inactivate viruses.…”

Section: Introductionmentioning

confidence: 99%

New insights into the altered binding capacity of pharmaceutical-grade human serum albumin: site-specific binding studies by induced circular dichroism spectroscopy

Tramarin¹,

Tedesco²,

Naldi³

et al. 2019

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis

Benmassaoud

Freeman

Roccarina

et al. 2020

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

BackgroundApproximately 20% of people with cirrhosis develop ascites. Several di erent treatments are available; including, among others, paracentesis plus fluid replacement, transjugular intrahepatic portosystemic shunts, aldosterone antagonists, and loop diuretics. However, there is uncertainty surrounding their relative e icacy. ObjectivesTo compare the benefits and harms of di erent treatments for ascites in people with decompensated liver cirrhosis through a network meta-analysis and to generate rankings of the di erent treatments for ascites according to their safety and e icacy. Search methodsWe searched CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, World Health Organization International Clinical Trials Registry Platform, and trials registers until May 2019 to identify randomised clinical trials in people with cirrhosis and ascites. Selection criteriaWe included only randomised clinical trials (irrespective of language, blinding, or status) in adults with cirrhosis and ascites. We excluded randomised clinical trials in which participants had previously undergone liver transplantation. Data collection and analysisWe performed a network meta-analysis with OpenBUGS using Bayesian methods and calculated the odds ratio, rate ratio, and hazard ratio (HR) with 95% credible intervals (CrI) based on an available-case analysis, according to National Institute of Health and Care Excellence Decision Support Unit guidance.Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis (Review)

show abstract

Long-term albumin administration in patients with cirrhosis and uncomplicated ascites: the use of serum albumin concentration for personalizing treatment

Cited by 3 publications

References 0 publications

Long‐term albumin administration in patients with cirrhosis and ascites: A meta‐analysis of randomized controlled trials

Long‐term albumin administration in patients with cirrhosis and ascites: A meta‐analysis of randomized controlled trials

New insights into the altered binding capacity of pharmaceutical-grade human serum albumin: site-specific binding studies by induced circular dichroism spectroscopy

Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis

Contact Info

Product

Resources

About